ONCOIMMUNE, INC.

Organization

ROCKVILLE, MD, US

Organizations

Please log in for detailed analytics

Patents Grantslast 30 patents

Information Patent Grant
Methods of use of CD24 for the prevention and treatment of leukemia...
- Patent number 11,911,441
- Issue date Feb 27, 2024
- Oncoimmune, Inc.
- Yang Liu
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Methods of use of soluble CD24 for treating lupus nephritis
- Patent number 11,571,461
- Issue date Feb 7, 2023
- Oncoimmune, Inc.
- Yang Liu
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Use of CD24 proteins for treating leptin-deficient conditions
- Patent number 10,799,558
- Issue date Oct 13, 2020
- Oncoimmune, Inc.
- Yang Liu
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Methods of use of soluble CD24 for therapy of rheumatoid arthritis
- Patent number 10,793,617
- Issue date Oct 6, 2020
- Oncoimmune, Inc.
- Xincheng Zheng
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Chimeric and humanized anti-human CTLA4 monoclonal antibodies and u...
- Patent number 10,618,960
- Issue date Apr 14, 2020
- Oncoimmune, Inc.
- Yang Liu
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Use of CD24 for lowering low-density lipoprotein cholesterol levels
- Patent number 10,369,197
- Issue date Aug 6, 2019
- Oncoimmune, Inc.
- Yang Liu
- G01 - MEASURING TESTING
Information Patent Grant
Uses of hypoxia-inducible factor inhibitors
- Patent number 9,877,998
- Issue date Jan 30, 2018
- Oncoimmune, Inc.
- Yang Liu
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Uses of hypoxia-inducible factor inhibitors
- Patent number 9,427,413
- Issue date Aug 30, 2016
- Oncoimmune, Inc.
- Yang Liu
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Grant
Methods of use of soluble CD24 for therapy of rheumatoid arthritis
- Patent number 8,895,022
- Issue date Nov 25, 2014
- Oncoimmune, Inc.
- Xincheng Zheng
- C07 - ORGANIC CHEMISTRY
Information Patent Grant
Methods of use of soluble CD24 for therapy of rheumatoid arthritis
- Patent number 8,808,697
- Issue date Aug 19, 2014
- Oncoimmune, Inc.
- Xincheng Zheng
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Please log in for detailed analytics

Patents Applicationslast 30 patents

Information Patent Application
METHODS OF USE OF SOLUBLE CD24 FOR TREATING SYSTEMIC LUPUS ERYTHEMA...
- Publication number 20220125874
- Publication date Apr 28, 2022
- OncoImmune, Inc.
- Yang LIU
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
METHODS OF USE OF CD24 FOR THE PREVENTION AND TREATMENT OF LEUKEMIA...
- Publication number 20210268061
- Publication date Sep 2, 2021
- OncoImmune, Inc.
- Yang Liu
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
METHODS OF USE OF CD24 FOR THE PREVENTION AND TREATMENT OF GRAFT VE...
- Publication number 20210228680
- Publication date Jul 29, 2021
- OncoImmune, Inc.
- Yang LIU
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
ANTI-CD24 COMPOSITIONS AND USES THEREOF
- Publication number 20210214458
- Publication date Jul 15, 2021
- OncoImmune, Inc.
- Yang Liu
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
Use of CD24 Proteins for Treating Leptin-Deficient Conditions
- Publication number 20210162006
- Publication date Jun 3, 2021
- OncoImmune, Inc.
- Yang LIU
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS
- Publication number 20210161991
- Publication date Jun 3, 2021
- OncoImmune, Inc.
- Yang LIU
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
METHODS OF USE OF SOLUBLE CD24 FOR TREATING ACQUIRED IMMUNE DEFICIE...
- Publication number 20210046154
- Publication date Feb 18, 2021
- OncoImmune, Inc.
- Yang Liu
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS
- Publication number 20200399345
- Publication date Dec 24, 2020
- OncoImmune, Inc.
- Xincheng Zheng
- C07 - ORGANIC CHEMISTRY
Information Patent Application
Chimeric and Humanized Anti-Human CTLA4 Monoclonal Antibodies and U...
- Publication number 20200283526
- Publication date Sep 10, 2020
- OncoImmune, Inc.
- Yang LIU
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
METHODS OF USE OF SOLUBLE CD24 FOR TREATING IMMUNE RELATED ADVERSE...
- Publication number 20200197485
- Publication date Jun 25, 2020
- OncoImmune, Inc.
- Yang LIU
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
METHODS OF USE OF SOLUBLE CD24 FOR NEUROPROTECTION AND REMYELINATION
- Publication number 20200181235
- Publication date Jun 11, 2020
- OncoImmune, Inc.
- Yang LIU
- C07 - ORGANIC CHEMISTRY
Information Patent Application
USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS
- Publication number 20200147167
- Publication date May 14, 2020
- OncoImmune, Inc.
- Yang Liu
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
USE OF CD24 FOR LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS
- Publication number 20190307841
- Publication date Oct 10, 2019
- OncoImmune, Inc.
- Yang LIU
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
CD80 and CD86 Binding Protein Compositions and Uses Thereof
- Publication number 20190263889
- Publication date Aug 29, 2019
- OncoImmune, Inc.
- Yang LIU
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS
- Publication number 20190255140
- Publication date Aug 22, 2019
- OncoImmune, Inc.
- Yang Liu
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
Chimeric and Humanized Anti-Human CTLA4 Monoclonal Antibodies and U...
- Publication number 20190127468
- Publication date May 2, 2019
- OncoImmune, Inc.
- Yang LIU
- C07 - ORGANIC CHEMISTRY
Information Patent Application
Use of CD24 Proteins for Treating Leptin-Deficient Conditions
- Publication number 20190038716
- Publication date Feb 7, 2019
- OncoImmune, Inc.
- Yang LIU
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS
- Publication number 20180177841
- Publication date Jun 28, 2018
- OncoImmune, Inc.
- Yang Liu
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
USE OF CD24 FOR LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS
- Publication number 20180110828
- Publication date Apr 26, 2018
- OncoImmune, Inc.
- Yang LIU
- G01 - MEASURING TESTING
Information Patent Application
USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS
- Publication number 20170239315
- Publication date Aug 24, 2017
- OncoImmune, Inc.
- Yang Liu
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS
- Publication number 20170233453
- Publication date Aug 17, 2017
- OncoImmune, Inc.
- Xincheng Zheng
- C07 - ORGANIC CHEMISTRY
Information Patent Application
USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS
- Publication number 20170035832
- Publication date Feb 9, 2017
- OncoImmune, Inc.
- Yang Liu
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS
- Publication number 20130136739
- Publication date May 30, 2013
- ONCOIMMUNE, INC.
- Xincheng Zheng
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE
Information Patent Application
USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS
- Publication number 20120264697
- Publication date Oct 18, 2012
- ONCOIMMUNE INC.
- Yang Liu
- A61 - MEDICAL OR VETERINARY SCIENCE HYGIENE

Please log in for detailed analytics

Trademarklast 30 trademarks

Information Trademark
90221101 - ONCOIMMUNE
- Serial number 90221101
- Filing date Sep 29, 2020
- OncoImmune, Inc.
- 42 - Scientific and technological services and research and design relating thereto
Information Trademark
90221098 - ONCOIMMUNE
- Serial number 90221098
- Filing date Sep 29, 2020
- OncoImmune, Inc.
- 42 - Scientific and technological services and research and design relating thereto
Information Trademark
90187540 - SACCOVID
- Serial number 90187540
- Filing date Sep 17, 2020
- OncoImmune, Inc.
- 44 - Medical services

NIH Research Projectlast 12 months

processing...

Count: 27

Research Projects

Information Research Project
SAC-COVID: An FDA-approved Phase III clinical trial evaluating the...
- Application id 10145067
- Award notice date Sep 21, 2020
Information Research Project
First in Human Phase I/II clinical trial of ONC-392: Preserving CTL...
- Application id 10010179
- Award notice date Apr 3, 2020
Information Research Project
A phase II dose expansion clinical trial testing the efficacy of CD...
- Application id 10019489
- Award notice date Mar 31, 2020
Information Research Project
Phase IIb trial of CD24Fc for GVHD prophylaxis, IND 127,363 (01/29/...
- Application id 9752976
- Award notice date Dec 31, 2019
Information Research Project
A phase II dose expansion clinical trial testing the efficacy of CD...
- Application id 9907609
- Award notice date Sep 17, 2019
Information Research Project
Evaluation of therapeutic efficacy and safety of novel small RNA ta...
- Application id 9844808
- Award notice date Sep 17, 2019
Information Research Project
A randomized, placebo-controlled, single-blinded clinical trial to...
- Application id 9776036
- Award notice date Aug 29, 2019
Information Research Project
A phase IIA trial for the safety and tolerability of CD24Fc in prop...
- Application id 9776876
- Award notice date Sep 12, 2018
Information Research Project
A phase IIA trial for the safety and tolerability of CD24Fc in prop...
- Application id 9567546
- Award notice date Aug 17, 2018
Information Research Project
Phase IIb trial of CD24Fc for GVHD prophylaxis, IND 127,363 (01/29/...
- Application id 9421167
- Award notice date Jul 30, 2018
Information Research Project
A phase IIA trial for the safety and tolerability of CD24Fc in prop...
- Application id 9409958
- Award notice date Sep 19, 2017
Information Research Project
Targeting endogenous sialidases for treatment of endotoxic shock
- Application id 8896416
- Award notice date Jul 16, 2015
Information Research Project
CD24 Targeting for Multiple Sclerosis: a First-In-Human Phase I Study
- Application id 8714084
- Award notice date Jul 29, 2014
Information Research Project
Targeting endogenous sialidases for treatment of endotoxic shock
- Application id 8781212
- Award notice date Jul 23, 2014
Information Research Project
CD24 Targeting for Multiple Sclerosis: a First-In-Human Phase I Study
- Application id 8573587
- Award notice date Aug 5, 2013
Information Research Project
Novel Therapeutics for Sepsis
- Application id 8057005
- Award notice date Aug 30, 2011
Information Research Project
Targeting host response to DAMP for therapy of Rheumatoid Arthritis
- Application id 8128116
- Award notice date Apr 18, 2011
Information Research Project
CD24 as Therapeutic Target for Multiple Sclerosis-phase II Competin...
- Application id 7769833
- Award notice date Mar 29, 2010
Information Research Project
CD24 as Therapeutic Target for Multiple Sclerosis-phase II Competin...
- Application id 7664468
- Award notice date Feb 11, 2009
Information Research Project
CD24 as Therapeutic Target for Multiple Sclerosis-phase II Competin...
- Application id 7393396
- Award notice date Jul 25, 2008
Information Research Project
CD24 as therapeutic target for multiple sclerosis-phase2
- Application id 6950269
- Award notice date Aug 18, 2005
Information Research Project
CD24 as therapeutic target for multiple sclerosis-phase2
- Application id 6833275
- Award notice date Sep 20, 2004
Information Research Project
GDP-bound Ras mutant RasN17N69 as a therapeutic agent
- Application id 6441406
- Award notice date Sep 6, 2002
Information Research Project
CD24 as a therapeutic target for Multiple Sclerosis
- Application id 6337172
- Award notice date Sep 24, 2001
Information Research Project
Human gene knock-in mice and anti-cancer antibodies
- Application id 6402462
- Award notice date Sep 17, 2001
Information Research Project
Wild type Ras as cancer therapeutic agent
- Application id 6408014
- Award notice date Sep 17, 2001
Information Research Project
Endothelial Cells as Gene Vehicles for MS Therapy
- Application id 6583824

ONCOIMMUNE, INC.

Organization

Patents Grantslast 30 patents

Methods of use of CD24 for the prevention and treatment of leukemia...

Methods of use of soluble CD24 for treating lupus nephritis

Use of CD24 proteins for treating leptin-deficient conditions

Methods of use of soluble CD24 for therapy of rheumatoid arthritis

Chimeric and humanized anti-human CTLA4 monoclonal antibodies and u...

Use of CD24 for lowering low-density lipoprotein cholesterol levels

Uses of hypoxia-inducible factor inhibitors

Uses of hypoxia-inducible factor inhibitors

Methods of use of soluble CD24 for therapy of rheumatoid arthritis

Methods of use of soluble CD24 for therapy of rheumatoid arthritis

Patents Applicationslast 30 patents

METHODS OF USE OF SOLUBLE CD24 FOR TREATING SYSTEMIC LUPUS ERYTHEMA...

METHODS OF USE OF CD24 FOR THE PREVENTION AND TREATMENT OF LEUKEMIA...

METHODS OF USE OF CD24 FOR THE PREVENTION AND TREATMENT OF GRAFT VE...

ANTI-CD24 COMPOSITIONS AND USES THEREOF

Use of CD24 Proteins for Treating Leptin-Deficient Conditions

USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS

METHODS OF USE OF SOLUBLE CD24 FOR TREATING ACQUIRED IMMUNE DEFICIE...

METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS

Chimeric and Humanized Anti-Human CTLA4 Monoclonal Antibodies and U...

METHODS OF USE OF SOLUBLE CD24 FOR TREATING IMMUNE RELATED ADVERSE...

METHODS OF USE OF SOLUBLE CD24 FOR NEUROPROTECTION AND REMYELINATION

USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS

USE OF CD24 FOR LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS

CD80 and CD86 Binding Protein Compositions and Uses Thereof

USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS

Chimeric and Humanized Anti-Human CTLA4 Monoclonal Antibodies and U...

Use of CD24 Proteins for Treating Leptin-Deficient Conditions

USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS

USE OF CD24 FOR LOWERING LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS

USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS

METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS

USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS

METHODS OF USE OF SOLUBLE CD24 FOR THERAPY OF RHEUMATOID ARTHRITIS

USES OF HYPOXIA-INDUCIBLE FACTOR INHIBITORS

Trademarklast 30 trademarks

90221101 - ONCOIMMUNE

90221098 - ONCOIMMUNE

90187540 - SACCOVID

NIH Research Projectlast 12 months

Research Projects

SAC-COVID: An FDA-approved Phase III clinical trial evaluating the...

First in Human Phase I/II clinical trial of ONC-392: Preserving CTL...

A phase II dose expansion clinical trial testing the efficacy of CD...

Phase IIb trial of CD24Fc for GVHD prophylaxis, IND 127,363 (01/29/...

A phase II dose expansion clinical trial testing the efficacy of CD...

Evaluation of therapeutic efficacy and safety of novel small RNA ta...

A randomized, placebo-controlled, single-blinded clinical trial to...

A phase IIA trial for the safety and tolerability of CD24Fc in prop...

A phase IIA trial for the safety and tolerability of CD24Fc in prop...

Phase IIb trial of CD24Fc for GVHD prophylaxis, IND 127,363 (01/29/...

A phase IIA trial for the safety and tolerability of CD24Fc in prop...

Targeting endogenous sialidases for treatment of endotoxic shock

CD24 Targeting for Multiple Sclerosis: a First-In-Human Phase I Study

Targeting endogenous sialidases for treatment of endotoxic shock

CD24 Targeting for Multiple Sclerosis: a First-In-Human Phase I Study

Novel Therapeutics for Sepsis

Targeting host response to DAMP for therapy of Rheumatoid Arthritis

CD24 as Therapeutic Target for Multiple Sclerosis-phase II Competin...

CD24 as Therapeutic Target for Multiple Sclerosis-phase II Competin...

CD24 as Therapeutic Target for Multiple Sclerosis-phase II Competin...

CD24 as therapeutic target for multiple sclerosis-phase2

CD24 as therapeutic target for multiple sclerosis-phase2

GDP-bound Ras mutant RasN17N69 as a therapeutic agent

CD24 as a therapeutic target for Multiple Sclerosis

Human gene knock-in mice and anti-cancer antibodies

Wild type Ras as cancer therapeutic agent

Endothelial Cells as Gene Vehicles for MS Therapy